Mutations in the NRF2-KEAP1 pathway are common in non-small cell lung cancer (NSCLC) and confer broad-spectrum therapeutic resistance, leading to poor outcomes. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.